Premium
Quality of life in patients of chronic lymphocytic leukemia using the EORTC QLQ‐C30 and QLQ‐CLL17 questionnaire
Author(s) -
Youron Padma,
Singh Charanpreet,
Jindal Nishant,
Malhotra Pankaj,
Khadwal Alka,
Jain Arihant,
Prakash Gaurav,
Varma Neelam,
Varma Subhash,
Lad Deepesh P.
Publication year - 2020
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.13503
Subject(s) - medicine , quality of life (healthcare) , socioeconomic status , ibrutinib , chronic lymphocytic leukemia , ethnic group , leukemia , gerontology , environmental health , population , nursing , sociology , anthropology
The quality of life (QoL) analysis is likely to differ by region, ethnicity, and questionnaires in comparison with age‐matched healthy controls. Methods The EORTC QLQ‐C30 and QLQ‐CLL17 questionnaire validated in regional languages were administered to 127 consecutive CLL and 100 age‐matched, healthy controls at a single center from 2018 to 2019. Results All groups of CLL patients either on wait and watch (W&W) or on treatment had significantly impaired QoL in all functional domains including global health compared to controls ( P < .0001). CLL patients had significantly higher symptom scores than controls in most domains ( P < .0001, 0.03 for diarrhea). There was no difference in the QoL by age or gender. Lower socioeconomic status patients had higher financial difficulty ( P = .02). Patients on CIT had the worst global health (OR 12.21 compared to patients on W&W) ( P = .03). Patients on ibrutinib had less worries/fears about health and functioning than patients who were on CIT ( P = .04). Conclusions Quality of life is severely affected in CLL patients on W&W. Global health status and worries about future health and functioning were major concerns. Socioeconomic status but not age or gender impacted QoL. Patients on ibrutinib had better QoL than on CIT.